Glaukos (GKOS) reported $106.66 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 24.6%. EPS of -$0.22 for the same period compares to -$0.70 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $102.72 million, representing a surprise of +3.84%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.33.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- United States: $75.07 million compared to the $71.54 million average estimate based on five analysts. The reported number represents a change of +30.1% year over year.
- Revenues- International: $31.59 million compared to the $31.35 million average estimate based on five analysts. The reported number represents a change of +13.1% year over year.
- Revenues- Corneal Health- International: $2.59 million versus the five-analyst average estimate of $2.78 million. The reported number represents a year-over-year change of -4.1%.
- Revenues- Corneal Health- United States: $15.94 million compared to the $15.50 million average estimate based on five analysts. The reported number represents a change of +1.5% year over year.
- Revenues- Glaucoma- International: $29.01 million versus the five-analyst average estimate of $28.57 million. The reported number represents a year-over-year change of +14.9%.
- Revenues- Glaucoma- United States: $59.13 million compared to the $56.03 million average estimate based on five analysts. The reported number represents a change of +40.8% year over year.
- Revenues- Corneal Health: $18.53 million versus $18.28 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change.
- Revenues- Glaucoma: $88.14 million compared to the $84.60 million average estimate based on five analysts. The reported number represents a change of +31.1% year over year.
View all Key Company Metrics for Glaukos here>>>
Shares of Glaukos have returned -5.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Glaukos Corporation (GKOS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
